Expanding Enterprise Value Through the Active Pursuit of M&A
First written in FY2019. 11 of 14 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2026.
30 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Company determined that this share acquisition would enable the Group to enter new business fields and expand its sales channels, contributing to the enhancement of corporate value over the medium to long term.」
Under its policy of making M&A a key growth strategy, the Company decided to make Marine Pro Foods a wholly owned subsidiary, thereby concretely advancing its expansion into new business fields and sales channels. - 2026-10-16AdvancedManagement Planning
「「その具体的な取り組みとして、株式会社マリン・プロフーズの株式取得契約を締結しております。」」
M&Aを成長手段とする方針について、マリン・プロフーズの100％株式取得契約を具体化している。 - 2026-10-06Advancedwww.nikkei.com
「The company plans to acquire all shares of マリン・プロフーズ from a fund of Daiwa PI Partners on the 30th.」
A specific transaction to acquire all shares of マリン・プロフーズ for approximately ¥5 billion has progressed under the policy of expanding corporate value through M&A. - 2026-10-06AdvancedM&A and Subsidiary Changes
「Our group positions M&A as an important growth strategy under the medium-term management plan, the New Value Creation 1K Project. At a meeting of the Board of Directors held on 6 October 2026, we resolved to acquire the shares of Marine Pro Foods Co., Ltd. and make it a subsidiary, hereinafter referred to as the acquisition.」
The policy of positioning M&A as an important growth strategy advanced to execution through a specific decision to make Marine Pro Foods a subsidiary for an acquisition price of ¥5,030 million. - FY2024RaisedAnnual report
「Using this cash as a funding source, we will make growth investments including more than ¥5 billion in the “Eggshell Membrane Bio-Manufacturing Project,” approximately ¥12 billion to construct a new pharmaceutical plant, and GABA development aimed at obtaining FDA GRAS certification in the United States, as well as investing approximately ¥10 billion in M&A to pursue non-continuous growth.」
The company explicitly stated its policy of using M&A as a growth driver, with plans to invest approximately ¥10 billion to pursue non-continuous growth, thereby specifying the scale of investment. - FY2023AdvancedAnnual report
「At a meeting of the Board of Directors held on 23 January 2023, the company resolved to establish PF Visionary Fund Investment Limited Partnership to rapidly accelerate innovation going forward in its antibody drug discovery and healthcare businesses based on its “ALAgene technology,” and entered into the agreement on the same date.」
In line with its policy of using M&A and investments as growth drivers, the company established PF Visionary Fund to accelerate innovation in the antibody drug discovery and healthcare fields. - FY2023-Q1RestatedAnnual report
「The company acquired shares of PF Capital Co., Ltd. and made it a subsidiary on 13 May 2022 (deemed acquisition date: 30 June 2022), and acquired shares of Onkyo Co., Ltd. and applied the equity method on 25 May 2022 (deemed acquisition date: 30 June 2022). Accordingly, the results of PF Capital Co., Ltd. and Onkyo Co., Ltd. have been included from the first quarter of the fiscal year under review.」
The company has reaffirmed the contribution to results from PF Capital and オンキヨー in line with its policy of using M&A and investments as growth drivers. - FY2022AdvancedAnnual report
「Through investments in オンキヨー株式会社 and ＥＮＥＧＧＯ株式会社, the company has begun developing new products and entering new markets as part of its alliance-building efforts.」
The company is pursuing the creation of growth through M&A, investments and alliances, including making PF Capital a subsidiary, investing in オンキヨー and others, and assuming the アンテグラル business. - FY2022-Q3AdvancedAnnual report
「To strengthen these antibody drug discovery projects, the company acquired the bioscience business of 株式会社アンテグラル through an absorption-type company split. The business has a leading track record and technological capabilities in domestic protein analysis.」
In line with its policy of using M&A and business transfers as growth drivers, the company assumed the bioscience business of アンテグラル effective 1 April 2022 and incorporated its drug discovery technologies. - FY2022-Q2AdvancedAnnual report
「The company acquired all shares of 明治薬品株式会社 and made it a subsidiary on 31 August 2021 (with a deemed acquisition date of 15 August 2021). Accordingly, 明治薬品株式会社’s results have been included in the consolidated results from the cumulative second quarter of the current fiscal year.」
Following the acquisition of all shares of 明治薬品, its results have been included in the consolidated results from the cumulative second quarter of the current fiscal year, and the contribution of the M&A to results was disclosed. - FY2022-Q1AdvancedAnnual report
「In addition to pursuing organic business growth, we have positioned M&A as an important growth strategy. We decided to acquire the shares of 明治薬品 because we believe that combining our R&D capabilities, product development capabilities and mail-order platform with 明治薬品’s manufacturing capabilities, sales channels and other management resources will expand earnings and enable the Group to achieve sustainable growth and enhance corporate value over the medium to long term.」
M&A was positioned as an important growth strategy, and 明治薬品 was made a wholly owned subsidiary at an acquisition price of ¥2,299 million. The company aims to combine its R&D capabilities, product development capabilities and direct-to-consumer platform with 明治薬品’s manufacturing capabilities and sales channels. - FY2021AdvancedAnnual report
「In addition to pursuing organic business growth, we have positioned M&A as an important growth strategy. We decided to acquire the shares of 明治薬品 because we believe that combining our R&D capabilities, product development capabilities and mail-order platform with 明治薬品’s manufacturing capabilities, sales channels and other management resources will expand earnings and enable the Group to achieve sustainable growth and enhance corporate value over the medium to long term.」
M&A was positioned as an important growth strategy, and all shares of 明治薬品 were acquired for ¥2,299 million. A specific transaction was completed to combine the company’s R&D capabilities, product development capabilities and direct-to-consumer platform with 明治薬品’s manufacturing capabilities and sales channels. - FY2021-Q1AdvancedAnnual report
「合同会社ｆｉｔコール東海 had previously provided outsourced call center services for 株式会社ファーマフーズコミュニケーション. The company decided to absorb and merge the two companies, as this was expected to strengthen the management structure, improve efficiency and generate cost synergies.」
In line with its policy of using M&A to expand corporate value, the company completed a transaction to acquire and absorb its call-center outsourcing provider through a merger. - FY2019First statedAnnual report
「We will actively pursue M&A to further expand corporate value.」
The company has explicitly stated its policy of actively using M&A to expand corporate value.